LIVER

Interfering with acute intermittent porphyria

Subjects

An RNA interference therapy (givosiran) targeting ALAS1 reduced the rate of attacks and improved other disease manifestations in patients with acute intermittent porphyria, the most common subtype of acute hepatic porphyria. A total of 94 patients were randomly assigned either givosiran (n = 48) or placebo (n = 46) in a phase III trial. In 89 patients with acute intermittent porphyria, the mean annualized attack rate was significantly lower in the givosiran group than the placebo group (decreased by 74%, P < 0.001; 3.2 versus 12.5). Other disease manifestations (including pain) also improved in the treatment group. However, a higher frequency of hepatic and renal adverse events was observed in the givosiran group than the placebo group. Givosiran is now approved by the FDA and the European Medicines Agency for adults with acute hepatic porphyria.

References

Original article

  1. Balwani, M. et al. Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria. N. Engl. J. Med. 382, 2289–2301 (2020)

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Katrina Ray.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ray, K. Interfering with acute intermittent porphyria. Nat Rev Gastroenterol Hepatol 17, 452 (2020). https://doi.org/10.1038/s41575-020-0335-3

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing